Azafaros
Carlo Incerti is Operating Partner at Forbion Capital Partners, Naarden, The Netherlands and offers over three decades of experience in the biopharmaceutical industry to Azafaros. He held several positions of increasing scope and responsibility at Genzyme Corporation, the company which pioneered the development of therapeutics for rare diseases. In the beginning, he worked at the European Headquarters in the Netherlands, then at the Corporate Headquarters in the US as Senior Vice President of Global Market Access and later as Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs.
Carlo is also Chairman of the Board at Molmed, a public Italian company active in cell and gene therapy, a member of the Board of EuropaBio and a founding member of the International Rare Diseases Research Consortium.
Prior to joining the industry, Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones. He received his medical degree at the University of Modena and Reggio Emilia.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Azafaros
Azafaros is developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential.